@goodtrials .@goodtrials Please also invite patients to give their perspective on what makes a good trial. Your guidance emphasizes the importance of their contribution It would be good to hear from them about what it looks like when it happens #GoodTrialsGrapevine https://t.co/wYwqWTjkNK

Good trials should include broad & varied trial populations to increase the relevance & usefulness of findings. Today, we hear from bioethicist @PhaikYeong whose work focuses on ethical research with underserved populations worldwide. #GoodtrialsGrapevine #goodtrials #CTD2023

The #GoodTrials guidance discusses the importance of proportionate, efficient and reliable capture of #data in #RCTs. Naomi Waithira from @MORUBKK highlights things to consider and things to avoid when planning data collection in a #clinicaltrial. #GoodTrialsGrapevine

Building quality into trial design is like constructing a sturdy house with a strong foundation. 🏠🔨 A simple but effective analogy from Emma Law, a clinical quality assurance expert from our host organization Protas, who shares her reflections for today’s #GoodTrialsGrapevine.

#Collaboration and #transparency are pivotal to maximizing benefit from research. In today’s #GoodTrialsGrapevine, @InfectiousMoYin of @ADVANCE__ID discusses the benefits of collaboration to boost the efficiency & quality of #clinicaltrials in Asia. 👉 https://t.co/c8zwItEPsm

@Healthy_Control We concur and that’s why our guidance includes the inputs from a diverse group of stakeholders, including patients. In the coming weeks, we will also be showcasing insights from patients in both our #GoodTrialsGrapevine series and other materials. Stay tuned!